Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash-to-Debt 2.07
NAS:INSM's Cash-to-Debt is ranked lower than
72% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:INSM: 2.07 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:INSM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86  Med: 10.73 Max: No Debt
Current: 2.07
0.86
No Debt
Debt-to-Equity 0.83
NAS:INSM's Debt-to-Equity is ranked lower than
80% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. NAS:INSM: 0.83 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:INSM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.75  Med: 0.14 Max: 3.85
Current: 0.83
-0.75
3.85
Debt-to-EBITDA -1.29
NAS:INSM's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. NAS:INSM: -1.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:INSM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.29  Med: -0.25 Max: 0
Current: -1.29
-1.29
0
Piotroski F-Score: 2
Altman Z-Score: -0.09
Beneish M-Score: -4.35
WACC vs ROIC
13.32%
-547.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
ROE % -76.44
NAS:INSM's ROE % is ranked lower than
66% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:INSM: -76.44 )
Ranked among companies with meaningful ROE % only.
NAS:INSM' s ROE % Range Over the Past 10 Years
Min: -361.62  Med: -44.96 Max: 195.47
Current: -76.44
-361.62
195.47
ROA % -48.55
NAS:INSM's ROA % is ranked lower than
61% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:INSM: -48.55 )
Ranked among companies with meaningful ROA % only.
NAS:INSM' s ROA % Range Over the Past 10 Years
Min: -129.17  Med: -37.18 Max: 180.06
Current: -48.55
-129.17
180.06
ROC (Joel Greenblatt) % -1870.46
NAS:INSM's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:INSM: -1870.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:INSM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -720550  Med: -1906.77 Max: -1133.76
Current: -1870.46
-720550
-1133.76
3-Year EBITDA Growth Rate -11.40
NAS:INSM's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:INSM: -11.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:INSM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -0.75 Max: 43.7
Current: -11.4
0
43.7
3-Year EPS without NRI Growth Rate -16.20
NAS:INSM's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NAS:INSM: -16.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:INSM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -0.2 Max: 59.5
Current: -16.2
0
59.5
GuruFocus has detected 1 Warning Sign with Insmed Inc NAS:INSM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:INSM's 30-Y Financials

Financials (Next Earnings Date: 2018-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» NAS:INSM's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q3 2017

INSM Guru Trades in Q3 2017

Steven Cohen 110,410 sh (New)
Jim Simons 55,887 sh (New)
Leon Cooperman 150,000 sh (New)
Louis Moore Bacon 50,000 sh (+100.00%)
Paul Tudor Jones 35,669 sh (+64.97%)
» More
Q4 2017

INSM Guru Trades in Q4 2017

Leon Cooperman 155,000 sh (+3.33%)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jim Simons 36,487 sh (-34.71%)
Paul Tudor Jones 9,022 sh (-74.71%)
» More
Q1 2018

INSM Guru Trades in Q1 2018

Paul Tudor Jones 15,066 sh (+66.99%)
Jim Simons Sold Out
Leon Cooperman 98,000 sh (-36.77%)
» More
Q2 2018

INSM Guru Trades in Q2 2018

Paul Tudor Jones Sold Out
Leon Cooperman 95,000 sh (-3.06%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with NAS:INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2018-06-30 Reduce -3.06%$20 - $29.72 $ 15.65-39%95,000
Leon Cooperman 2018-03-31 Reduce -36.77%0.07%$21.69 - $32.99 $ 15.65-41%98,000
Leon Cooperman 2017-12-31 Add 3.33%0.01%$26.43 - $31.78 $ 15.65-47%155,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ESPR, SZSE:002030, BOM:539268, NAS:ARNA, NAS:CORT, NYSE:CBM, NAS:AIMT, NAS:ENTA, HKSE:06826, NAS:MYOK, NAS:ACAD, NAS:DNLI, NAS:ICPT, XMCE:ALM, NAS:XLRN, SZSE:002287, NAS:GBT, NAS:SPPI, NAS:MDGL, XKRX:095700 » details
Traded in other countries:IM8N.Germany,
Headquarter Location:USA
Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases.

Insmed Inc is a global biotechnology company that is focused on developing novel therapies for rare diseases. The company works to develop and commercialize therapies that focus primarily on lung diseases. Insmed is focused broadly on rare disease therapeutics and prioritizing its current therapeutic focus in the fields of pulmonology and infectious disease. The company's strategy includes licensing its patents and pending patent applications. The company's primary businesses are within the U.S., Europe, and Canada, while also maintaining operations in other international markets as well.

Top Ranked Articles about Insmed Inc

Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)
October 11, 2018
Read more...
Insmed Extends Patent Protection in Japan to 2033
October 4, 2018
Read more...
Insmed Extends Patent Protection in Japan to 2033
October 4, 2018
Read more...
Insmed to Present at Two October Conferences
October 1, 2018
Read more...
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative T
September 28, 2018
Read more...
Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine
September 17, 2018
Read more...
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options
August 7, 2018
Read more...
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options
August 7, 2018
Read more...
Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018
July 26, 2018
Read more...
Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
June 15, 2018
Read more...

Ratios

vs
industry		 vs
history
PB Ratio 3.26
INSM's PB Ratio is ranked lower than
53% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INSM: 3.26 )
Ranked among companies with meaningful PB Ratio only.
INSM' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.93 Max: 105
Current: 3.26
0.45
105
EV-to-EBIT -3.64
INSM's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. INSM: -3.64 )
Ranked among companies with meaningful EV-to-EBIT only.
INSM' s EV-to-EBIT Range Over the Past 10 Years
Min: -215.2  Med: -7 Max: 163.9
Current: -3.64
-215.2
163.9
EV-to-EBITDA -3.69
INSM's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. INSM: -3.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -256.4  Med: -7.1 Max: 317.3
Current: -3.69
-256.4
317.3
Current Ratio 14.14
INSM's Current Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. INSM: 14.14 )
Ranked among companies with meaningful Current Ratio only.
INSM' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.32 Max: 50.67
Current: 14.14
0.53
50.67
Quick Ratio 14.14
INSM's Quick Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. INSM: 14.14 )
Ranked among companies with meaningful Quick Ratio only.
INSM' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.32 Max: 50.67
Current: 14.14
0.53
50.67

Buy Back

vs
industry		 vs
history
3-Year Average Share Buyback Ratio -15.40
INSM's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. INSM: -15.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119  Med: -25.65 Max: -5.4
Current: -15.4
-119
-5.4

Valuation & Return

vs
industry		 vs
history
Price-to-Net-Cash 4.30
INSM's Price-to-Net-Cash is ranked higher than
56% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. INSM: 4.30 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.57  Med: 5.06 Max: 197.5
Current: 4.3
0.57
197.5
Price-to-Net-Current-Asset-Value 4.13
INSM's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. INSM: 4.13 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 4.86 Max: 156.67
Current: 4.13
0.52
156.67
Price-to-Tangible-Book 3.85
INSM's Price-to-Tangible-Book is ranked lower than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. INSM: 3.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51  Med: 4.59 Max: 85
Current: 3.85
0.51
85
Earnings Yield (Greenblatt) % -27.42
INSM's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. INSM: -27.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8315.3  Med: -12.1 Max: 8748.9
Current: -27.42
-8315.3
8748.9

More Statistics

EPS (TTM) $ -3.46
Beta1.71
Volatility42.58%
52-Week Range $15.30 - 33.94
Shares Outstanding (Mil)77.04

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 4 65 201 463
EBIT (Mil $) -295 -234 -119 133
EBITDA (Mil $) -288 -223 -178
EPS ($) -4.04 -2.73 -1.50 1.24
EPS without NRI ($) -4.04 -2.73 -1.50 1.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for NAS:INSM

Headlines

Articles On GuruFocus.com
Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Oct 11 2018 
Insmed Extends Patent Protection in Japan to 2033 Oct 04 2018 
Insmed Extends Patent Protection in Japan to 2033 Oct 04 2018 
Insmed to Present at Two October Conferences Oct 01 2018 
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Sep 28 2018 
Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disea Sep 17 2018 
Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semic Aug 17 2018 
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for th Aug 07 2018 
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for th Aug 07 2018 
Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018 Jul 26 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}